NCT03021304 - Study of Mepolizumab Safety Syringe in Asthmatics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

August 8, 2017

Study Completion Date

August 8, 2017

Conditions

Asthma

Interventions

DRUG

Mepolizumab

It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.

Trial Locations (15)

35243

GSK Investigational Site, Birmingham

45231

GSK Investigational Site, Cincinnati

90025

GSK Investigational Site, Los Angeles

123095

GSK Investigational Site, Moscow

198328

GSK Investigational Site, Saint Petersburg

620109

GSK Investigational Site, Yekaterinburg

29118-2040

GSK Investigational Site, Orangeburg

J6E 2B4

GSK Investigational Site, Saint-Charles-Borromée

G1V 4G5

GSK Investigational Site, Sainte-Foy

1105 AZ

GSK Investigational Site, Amsterdam

8934 AD

GSK Investigational Site, Leeuwarden

8025 AB

GSK Investigational Site, Zwolle

SE-581 85

GSK Investigational Site, Linköping

SE-221 85

GSK Investigational Site, Lund

SE-141 86

GSK Investigational Site, Stockholm